CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...